

David J. Pinsky et al.  
U.S. Serial No.:09/053,871  
Filed: April 1, 1998  
Page 2

Final Office Action is now due March 13, 2001. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:

In the claims:

Please cancel claims 1-28, 31-32, 35, 37 and 38 without prejudice to applicants' right to pursue the subject matter of these claims in a future application. Please amend claims 29, 36 and 40.

A clean version of claims 29, 36 and 40 as amended are set forth below:

C1  
--29.(amended) A method of inhibiting clot formation in a subject which comprises adding to blood an amount of an inactive recombinant mutein in an amount effective to inhibit clot formation in the subject but which does not significantly interfere with hemostasis when the blood is administered to a patient,

wherein the inactive recombinant mutein comprises:

- (a) a proteolytically inactive recombinant mutein of Factor IX, or
- (b) a proteolytically inactive recombinant mutein of Factor IXa

and wherein the recombinant mutein comprises a

a

94